ABVC BioPharma Inc美股招股说明书(2025-08-15版)

Prospectus Supplement No. 4 Dated August 15, 2025(To Prospectus Dated April 5, 2024) ABVC BioPharma, Inc.11,714,683 Shares of Common Stock This Prospectus Supplement No. 4 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc.,a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated April 5, 2024, as later updated (the “Prospectus”), with thefollowing attached document which we filed with the Securities and Exchange Commission: A.Our Quarterly Report on Form 10-Q for the three months ended June 30, 2025, filed with the Securities Exchange Commission onAugust 13, 2025. This Prospectus Supplement should be read in conjunction with the Prospectus, which is required to be delivered with thisProspectus Supplement. This Prospectus Supplement updates, amends and supplements the information included in the Prospectus. Ifthere is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on theinformation in this Prospectus Supplement. This Prospectus Supplement is not complete without, and may not be delivered or utilized except in connection with, theProspectus, including any amendments or supplements to it. The purchase of the securities offered through the Prospectus involves a high degree of risk. Before making anyinvestment in our common stock and/or warrants, you should carefully consider the risk factors section beginning on page 8 ofthe Prospectus. You should rely only on the information contained in the Prospectus, as supplemented or amended by this ProspectusSupplement and any other prospectus supplement or amendment thereto. We have not authorized anyone to provide you withdifferent information. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the adequacy or accuracy of the Prospectus. Any representation to the contrary is a criminaloffense. The date of this Prospectus Supplement is August 15, 2025. Index to Filings UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJune 30, 2025 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number001-40700 ABVC BioPharma, Inc.(Exact name of Registrant as specified in its charter) Nevada26-0014658State or jurisdiction ofIRS Employer 44370 Old Warm Springs Blvd.Fremont, CA 94538Tel: (510) 668-0881(Address and telephone number of principal executive offices) (Former name, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on whichregistered Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act duringthe past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the last 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ☐Accelerated filer☒Smaller reporting companyEmerging growth company Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 12, 2025, there were 23,541,824shares of common stock, par value per share $0.001, issued and outstanding. TABLE OF CONTENTS PART IFINANCIAL INFORMATIONF-1Item 1.Financial Statements (Unaudited)F-1Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024F-1Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three andSix Months Ended June 30, 2025 and 2024 (Restated)F-2Unaudited Condensed Consolidated Statements of Cash Flows for the Six months Ended June 30, 2025 and2024 (Restated)F-3Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Three and